This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geroni, C. Articles by Broggini, M. Search for Related Content PubMed PubMed Citation Articles by Geroni, C. Articles by Broggini, M.

Brostallicin, a Novel Anticancer Agent Whose Activity Is Enhanced upon Binding to Glutathione¹

Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri," 20157 Milan, Italy [S. M., E. G., T. C., M. D., M. B.]; Agri-Food Molecular Sciences Department, Università degli Studi di Milano, 20100 Milan, Italy [E. R.]; and Pharmacia Corporation, Discovery Research Oncology 20014 Nerviano (Milan), Italy [C. G., P. C., R. B., M. H.]

Brostallicin (PNU-166196) is a synthetic -bromoacrylic, second-generationDNA minor groove binder structurally related to distamycin A, presently in Phase II trials in Europe and the United States. The compound shows broad antitumor activity in preclinical models and dramatically reduced in vitro myelotoxicity in human hematopoietic progenitor cells compared with that of other minor groove binders. Brostallicin showed a 3-fold higher activity in melphalan-resistant L1210 murine leukemia cells than in the parental line (IC₅₀ = 0.46 and 1.45 ng/ml, respectively) under conditions in which the cytotoxicity of conventional antitumor agents was either unaffected or reduced. This melphalan-resistant cell line has increased levels of glutathione (GSH) in comparison with the parental cells. Conversely, GSH depletion by buthionine sulfoximine in a human ovarian carcinoma cell line (A2780) significantly decreased both the cytotoxic and the proapoptotic effects of brostallicin. In one experiment, human glutathione S-transferase (GST-) cDNA was transfected into A2780 cells, and four clones of A2780 with different expression levels of GST- were generated (i.e., two clones with high and two clones with low GST- expression). A 2–3-fold increase in GST- levels resulted in a 2–3-fold increase in cytotoxic activity of brostallicin. Similar results were obtained for GST--transfected human breast carcinoma cells (MCF-7). Brostallicin showed 5.8-fold increased cytotoxicity in GST--transfected versus empty vector-transfected cells with low GST- expression. In an in vivo experiment, A2780 clones were implanted into nude mice. The antitumor activity of brostallicin was higher in the GST--overexpressing tumors without increased toxicity. Regarding the mechanism of action, brostallicin interacts reversibly with the DNA minor groove TA-rich sequences but appears unreactive in classical in vitro DNA alkylation assays. We speculated that an intracellular reactive nucleophilic species, e.g., GSH, could react with the -bromoacrylamide moiety functions. Experiments on the interaction with plasmid DNA showed a change of the DNA topology from supercoiled to circular form (nicking) in the presence of GSH, whereas no change was found in its absence. In vitro incubations of brostallicin were performed with the human recombinant GST isoenzymes A1-1, M1-1, and P1-1 (, µ, and isoenzymes, respectively) in the presence of GSH. The decrease in brostallicin levels was monitored in these incubations; the rate of loss (and therefore brostallicin metabolism) was significantly higher for the M1-1 and P1-1 isoenzymes than for the A1-1 isoenzyme.

This article has been cited by other articles:

				A. V. Vargiu, P. Ruggerone, A. Magistrato, and P. Carloni Dissociation of minor groove binders from DNA: insights from metadynamics simulations Nucleic Acids Res., October 1, 2008; 36(18): 5910 - 5921. [Abstract] [Full Text] [PDF]

				A. C. Lockhart, M. Howard, K. R. Hande, B. J. Roth, J. D. Berlin, F. Vreeland, A. Campbell, E. Fontana, F. Fiorentini, C. Fowst, et al. A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors Clin. Cancer Res., January 15, 2004; 10(2): 468 - 475. [Abstract] [Full Text] [PDF]

				M. A. Sabatino, T. Colombo, C. Geroni, S. Marchini, and M. Broggini Enhancement of in Vivo Antitumor Activity of Classical Anticancer Agents by Combination with the New, Glutathione-Interacting DNA Minor Groove-Binder, Brostallicin Clin. Cancer Res., November 1, 2003; 9(14): 5402 - 5408. [Abstract] [Full Text] [PDF]

				A. J. ten Tije, J. Verweij, A. Sparreboom, A. van der Gaast, C. Fowst, F. Fiorentini, J. Tursi, A. Antonellini, M. Mantel, C. M. Hartman, et al. Phase I and Pharmacokinetic Study of Brostallicin (PNU-166196), a New DNA Minor-Groove Binder, Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer Clin. Cancer Res., August 1, 2003; 9(8): 2957 - 2964. [Abstract] [Full Text] [PDF]